Este fracaso A corto plazo, es una mala noticia para los pacientes ... Esto significa que el medicamento no estará disponible como una alternativa a la quimioterapia a corto plazo ... Pero es una buena noticia para decenas de empresas de Biotecnología ... Bristol seguramente al fracasar en solitario con Opdivo intentara buscar una combinación con otro Farmaco que Mejore los actuales resultados en solitario con Opdivo ...
*************************************
**********************
**********
*****
Bristol clobbered—shares drop 17%—after failed drug test .
Evelyn Cheng | Meg Tirrell /// CNBC.com . 6 August 2016 .
Shares of Bristol-Myers Squibb plunged more than 17 percent in morning trading Friday after its important cancer drug failed to meet targets in a late-stage study.
Shares of Bristol-Myers' competitors who have their own versions of the cancer therapy rose on the news. Bristol-Myers' shares ended the day down nearly 16 percent, while shares of Merck surged more than 10 percent.
Bristol-Myers' drug Opdivo, which is already approved to treat some types of cancer, before Friday was seen as a treatment that could significantly boost the company's growth.
In the study known as CheckMate -026, the company was trying to see if Opvido would be successful in treating "a broad patient population" of people with advanced non-small cell lung cancer, which accounts for the vast share of lung cancers. Up to 200,000 people in the United States are annually diagnosed with non-small lung cancer, which is often fatal.
Bristol-Myers CEO Giovanni Caforio said in a release that he was "disappointed" with the result but management remains "committed to improving patient outcomes through our comprehensive development program." Caforio also pointed to another ongoing trial, called CheckMate -227, of Opdivo in combination with the therapy Yervoy, as well as Obdivo combined with chemotherapy.
...